TABLE.

Clinical Trials with MVA-5T4

Clinical Trials.gov Identifier	Trial Phase	Trial Format	Disease	MVA-5T4 Doses	Pfu/dose	Concomitant Systemic Treatment	Evaluable Patients	Study Status	Reference
Single Agent Studies
None	I/II	Open-label	CRC	5	Dose escalation to 5 ×10^8	None	17	Completed	[22]
NCT00259844	II	Open-label	CRC	6	Not stated	None (surgery)	16	Completed	[23]
Combination Studies
None	II	Open-label	CRC	6	5 × 10^8	5-FU/leukovorin/oxaliplatin	11	Completed	[24]
None	II	Open-label	CRC	6	5 × 10^8	5-FU/leukovorin/irinotecan	12	Completed	[25]
NCT00445523	II	Single center open-label	RCC	10	Not stated	None vs IFN-α	Not stated	Completed	[26]
None	I/II	Open-label	RCC	Not Stated	Not stated	IFN-α	11	Closed	[27]
NCT00325507	II	Single center open-label	RCC	8	Not stated	IL-2 (low dose)	25	Completed	[26, 28]
NCT00083941	II	Single center open-label	RCC	8	Not stated	IL-2 (high dose)	22	Completed	[29]
NCT00397345	III	Multicenter randomized double-blind placebo- controlled	RCC	13	1 × 10^9	IFN-αIL-2 Sunitinib	733	Closed	[30]
NCT00448409	II	Single center open-label	HRPC	11	5 × 10^8	None vs GM-CSF	24	Completed	[32]
NCT00521274	II	Single center open-label	HRPC	12	Not stated	Docetaxel	60 (planned)	Stopped by Sponsor	[33]

Notes: abbreviations: pfu = plaque forming unit; CRC= colorectal cancer; RCC = renal cell carcinoma; HRPC = hormone-refractory prostate cancer; 5-FU = 5-fluoruracil; IFN-α = interferon-alfa; IL-2 = interleukin-2; GM-CSF = granulocyte-macrophage colony stimulating factor.